Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02682225

Recruitment Status : Completed

First Posted : February 15, 2016

Last Update Posted : March 16, 2017

Sponsor:

Information provided by (Responsible Party):

Janssen Research & Development, LLC

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	January 9, 2017
Actual Study Completion Date :	January 9, 2017

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Perez-Ruixo C, Rossenu S, Zannikos P, Nandy P, Singh J, Drevets WC, Perez-Ruixo JJ. Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. Clin Pharmacokinet. 2020 Oct 31. doi: 10.1007/s40262-020-00953-4. [Epub ahead of print]

To Top